⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

ANTHEM - Investment Analysis: Buy Signal or Bull Trap?

← Back to List

⭐ Rating: 2.3

Last Updated Time : 10 Sept 26, 03:41 am

Key Parameters

⭐ Investment Rating: 2.3

ROE24.3 %
ROCE32.0 %
PEG Ratio3.21
Dividend Yield0.21 %
Debt to equity0.02
PAT Qtr102 Cr.
PAT Prev Qtr211 Cr.
Qtr Profit Var-31.2 %
Show all parameters (20 more)
Stock CodeANTHEM
Market Cap53,120 Cr.
Current Price943 ₹
High / Low978 ₹
Stock P/E82.7
Book Value56.7 ₹
Face Value2.00 ₹
DMA 50858 ₹
DMA 200772 ₹
Chg in FII Hold1.29 %
Chg in DII Hold1.93 %
RSI63.8
MACD30.1
Volume9,78,174
Avg Vol 1Wk8,62,100
Low price579 ₹
High price978 ₹
52w Index91.3 %
EPS11.1 ₹
Industry PE55.4

🏭 Industry

The pharmaceutical sector is generally characterized by long product development cycles and regulatory hurdles, creating a competitive landscape with varying degrees of risk and reward. However, companies with robust R&D capabilities and a focus on niche therapeutic areas can enjoy sustainable growth and generate attractive returns over the long term.

✅ Positive

Anthem Biosciences demonstrates robust profitability with a 32% ROCE and a significant PAT growth in the last two quarters, indicating strong operational efficiency and revenue generation. The company’s low debt-to-equity ratio (0.02) further enhances its financial stability and capacity for future investments, contributing to a durable business model.

⚠️ Limitation

Despite strong recent profitability, the exceptionally high P/E ratio of 82.7 compared to the industry average of 55.4 suggests that the stock is currently trading at a premium valuation, potentially vulnerable to corrections if growth expectations aren’t met. Furthermore, the PEG ratio of 3.21 reinforces this elevated valuation, indicating that earnings are growing faster than the market deems reasonable.

📈 Company Positive News

The ‘Buy’ recommendation from Univest and a second consecutive 52-week high signal positive investor sentiment and potential for continued upward momentum, reflecting strong performance relative to expectations.

🧾 Long-Term Outlook

An entry price zone between 880 ₹ and 920 ₹ would represent a reasonable point of value given the current market conditions and the company's strong fundamentals. A holding period of 5-7 years is recommended, focusing on consistent dividend income alongside potential capital appreciation as Anthem Biosciences continues to execute its growth strategy. The stock warrants careful monitoring due to the premium valuation but offers a durable investment opportunity driven by sustainable profitability and a solid competitive position.

Choose Technical Analysis or Fundamental Analysis above to load it.

How ANTHEM Rates Across All Strategies

★ 2.3
Entry Price: 935 ₹ – Initiate a long position with an entry price jus…
Investment
★ 2.3
You're viewing this analysis below.

NIFTY 50 · Investment

NEXT 50 · Investment

MIDCAP · Investment

SMALLCAP · Investment